AngioDesign (AgeTech UK) ^Covid-19

ACE inhibitors, enzyme structure determination and inhibitor design. AngioDesign (UK) Ltd is a drug discovery and development company, registered under the laws of England and Wales, and focused on the design of novel, next-generation drugs for proven disease targets. AngioDesign applies structure-guided and computer-aided drug design to proven disease targets and develops 2nd-generation drugs with superior efficacy and side effect profiles. Utilising AngioDesign's patented technology, NCEs (new chemical entities) are advanced along validated drug development paths with clear blockbuster potential in proven therapeutic areas.